July 07, 2016
Hospira and Amgen are crossing swords in Delaware federal court over a new Federal Circuit ruling on the obligations of biosimilars makers, debating whether it means that companies can enforce a key provision in the Biologics Price Competition and Innovation Act.
February 16, 2016
A Pfizer Inc. subsidiary urged a federal judge in Delaware on Tuesday to toss a claim that it failed to share full information about a potential new product similar to an Amgen Inc. anemia drug, arguing that Congress never authorized private actions to enforce the disclosures.
October 14, 2015
Amgen Inc. can't enforce a federal law that calls for biosimilar makers to share manufacturing information and provide advance notice of sales, Hospira Inc. told a Delaware federal judge on Tuesday.
September 21, 2015
Amgen Inc. on Friday sued Hospira Inc. in Delaware federal court for allegedly violating information-sharing and advance-notice provisions of the Biologics Price Competition and Innovation Act, adding to a flurry of litigation that will decide how quickly biosimilars get to market.